BPC-157 (Body Protection Compound-157, also written BPC157) is a synthetic 15-amino-acid peptide copied from a protein in human gastric juice, used for tendon, joint and gut healing. As of November 2026 it has no FDA approval, but an October 28, 2026 HHS policy lets licensed 503A pharmacies compound single-ingredient BPC-157 with a prescription.
BPC-157 is the most widely used healing peptide in the world. Not the most studied in clinical trials, those are GLP-1 drugs, but the most used by people actually trying to fix something: a torn tendon, a wrecked gut, a joint that won't stop hurting.
🔑 Key Takeaways
- Status as of November 2026: the FDA's advisory committee voted 8–6 (1 abstention) for BPC-157 on July 23, 2026, and under HHS's October 28, 2026 policy, licensed 503A pharmacies may compound single-ingredient BPC-157 on a prescription while the policy stands. It still has no FDA approval
- BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide fragment derived from a protein naturally found in human gastric juice. It accelerates healing across tendons, ligaments, muscles, gut lining, nerves, and skin
- The primary mechanism is angiogenesis: BPC-157 builds new blood vessels at injury sites, dramatically increasing oxygen and nutrient delivery to damaged tissue. It also upregulates growth factors and modulates nitric oxide signaling
- Gut healing is the most biologically direct application because BPC-157 originates from the gastric system. NSAID damage, leaky gut, IBS symptoms, and post-antibiotic gut issues respond fastest
- Tendon and ligament repair is the most common use case. Injuries that have persisted for months often begin improving within 1 to 2 weeks
- BPC-157 peptide is available as injectable (subcutaneous) and oral capsules. Injectable provides systemic benefits. Oral delivers directly to the GI tract for gut-specific goals
- Side effects are minimal: injection site redness, occasional nausea. No serious adverse events have been widely reported at standard doses
- Often stacked with TB-500 (the Wolverine Stack) for amplified healing, covering both blood vessel formation and cell migration
This is the full picture of BPC-157: what it is, how it works, every documented benefit, dosing, side effects, stacking, and how to use it.
BPC-157 FDA Status in 2026: Reclassification & What Changed
The legal and regulatory landscape for BPC-157 shifted meaningfully in 2026. If you're reading anything written before October 28, 2026, the rules have changed: the July advisory vote is over, and HHS has since issued a compounding policy.
BPC-157 regulatory timeline (as of November 2026):
- September 29, 2023: FDA placed BPC-157 in Category 2 of its 503A bulk-substance interim policy (substances that "may present significant safety risks"), which shut off pharmacy compounding (FDA Category 2 list, 2024 archive).
- April 2026: The nominations were withdrawn and BPC-157 left Category 2. FDA's page (content current as of April 22, 2026) now lists it under "nominated but withdrawn" (FDA). Leaving Category 2 did not by itself make it legal to compound.
- July 23, 2026: FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 with 1 abstention to recommend adding BPC-157 to the 503A bulks list, against the recommendation of FDA staff. The vote is advisory (RAPS; our PCAC vote recap).
- October 28, 2026: HHS issued an interim enforcement-discretion policy, published in the Federal Register on October 30, 2026 (91 FR 68526). HHS will not take action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate for subcutaneous, intramuscular, oral or topical use, with a patient-specific prescription and a certificate of analysis from an FDA-registered manufacturer (Baker Donelson summary; our HHS peptide policy explainer).
- Blends are excluded: the policy covers only products with a single active ingredient, so BPC-157 + TB-500 (Wolverine), GLOW and KLOW blends are not covered.
- Still pending: FDA rulemaking to place BPC-157 on the 503A bulks list. BPC-157 has no FDA approval for any use, and enforcement discretion is not approval.
- Peptide vendors (Ascension, others) remain the main supply channel for people buying without a prescription. Their vials are labelled for laboratory use only, and the HHS policy does not cover them: it applies to pharmacies and physicians, not online sellers.
- WADA: BPC-157 is on the World Anti-Doping Agency Prohibited List (Section S2, peptide hormones). Athletes in tested sport should not use it under any route.
Practical translation: for anyone outside competitive testing, BPC-157 is more accessible in November 2026 than at any point since 2023. A doctor can prescribe single-ingredient BPC-157 and a 503A pharmacy can fill it, but the policy is interim and HHS says it can revisit it if a safety or quality problem appears. For current vendor verification and compounded-route status see our BPC-157 legal sourcing guide and the broader FDA AdCom peptide restrictions briefing.
What Is BPC-157?
A fragment of a protein your stomach already makes.
BPC-157 stands for Body Protection Compound-157. It's a synthetic version of a 15-amino acid sequence found in human gastric juice, the digestive fluid your stomach produces. The natural protein (called BPC) plays a role in protecting and repairing the GI tract. BPC-157 is a stable fragment of that protein, engineered to survive longer and produce stronger effects than the natural version.
The peptide was first characterized in the 1990s. Since then, it has been studied in hundreds of models across tissue types: tendons, ligaments, muscles, bones, gut lining, blood vessels, nerves, and skin. No human clinical trials have reached Phase 3 (a common criticism), but the breadth of consistent data across models, combined with extensive community use, has made it the most popular healing peptide available.
BPC-157 has no FDA approval for any indication. Since October 28, 2026 it can be compounded by 503A pharmacies with a prescription under an interim HHS policy, and it is also sold by peptide suppliers. FDA has not yet completed the rulemaking that would add it to the 503A bulks list.
BPC-157 Human Evidence So Far
Three small studies. That's the whole human record.
Every human study of BPC-157 published so far is a small pilot or chart review without a control group, and all three share the same lead author working in private clinics. A 2026 systematic review found these 3 studies, 30 people in total, and rated the certainty of evidence "very low" (Poolton et al., Acta Orthop Belg 2026, PMID 42885452).
What this means for you: the reports are encouraging and no serious harm has been recorded, but 30 people without a comparison group cannot show that BPC-157 works or that it is safe long term. The doses above are the doses those studies used, not a protocol to copy.
How BPC-157 Works
Four mechanisms, all running simultaneously.
Most healing compounds target one pathway. BPC-157 operates across several, which explains why it shows results across so many tissue types:
- Angiogenesis: BPC-157 stimulates new blood vessel formation at injury sites by upregulating VEGF (vascular endothelial growth factor). More blood supply means more oxygen, more nutrients, and faster clearance of inflammatory waste. This is the primary mechanism behind accelerated healing.
- Growth factor upregulation: Beyond VEGF, BPC-157 increases activity of EGF (epidermal growth factor), FGF (fibroblast growth factor), and other repair-signaling molecules. These drive tissue regeneration at the cellular level.
- Nitric oxide modulation: BPC-157 interacts with the nitric oxide system, which regulates blood flow, inflammation, and neurotransmitter activity. This pathway connects to both its cardiovascular and neuroprotective effects.
- Anti-inflammatory signaling: Reduces pro-inflammatory cytokines at injury sites without the systemic immunosuppression of NSAIDs or corticosteroids. The inflammation goes down, but your immune system stays functional.
The combination is why BPC-157 doesn't just help one tissue type. It supports the entire repair infrastructure.
BPC-157 Benefits
Every documented effect, organized by strength of evidence and user experience.
Tendon and Ligament Healing
The most common reason people use BPC-157.
Tendons heal slowly because they have poor blood supply compared to muscles. BPC-157 directly addresses this by building new vasculature into the damaged tissue. Studies show accelerated healing of Achilles tendon injuries, MCL tears, rotator cuff damage, and patellar tendinopathy.
What users consistently report: tendon pain that has lingered for months begins improving within 1 to 2 weeks. Full resolution typically takes 4 to 8 weeks. The improvement isn't just pain masking. The tissue is structurally repairing. For dosing details, see the BPC-157 dosage page.
Gut Healing
The benefit with the strongest biological logic.
BPC-157 comes from the gut. It's a fragment of a gastric protection protein. Its effects on the GI lining are the most directly supported of any application:
- Heals NSAID-induced stomach and intestinal ulcers (ibuprofen, naproxen, aspirin damage)
- Repairs intestinal permeability ("leaky gut") by restoring tight junction integrity
- Reduces GI inflammation relevant to IBS, IBD-related symptoms, and post-antibiotic dysbiosis
- Protects against alcohol-induced gastric lesions
- Accelerates healing of inflammatory bowel damage
Gut benefits appear fastest. Reduced bloating, less post-meal discomfort, and improved regularity often within the first week. This is also why oral BPC-157 capsules are popular for gut-specific goals.
Muscle Recovery
Faster repair between training sessions.
BPC-157 accelerates muscle fiber regeneration through the same angiogenic and growth factor mechanisms that help tendons. For athletes and anyone training hard, this means less soreness, faster recovery between sessions, and the ability to maintain volume through minor strains. Crushed muscle tissue in studies showed significantly faster regeneration with BPC-157 compared to controls.
Joint Pain and Inflammation
Even people using BPC-157 for a specific injury report improvement in other joints. The systemic anti-inflammatory effect reduces inflammatory cytokines throughout the body. Particularly relevant for people with multiple joint complaints or chronic inflammatory conditions.
Nerve Healing
One of the less discussed applications.
BPC-157 shows neuroprotective effects and accelerated peripheral nerve regeneration. Studies demonstrate improved recovery from nerve crush injuries and protection against neurotoxic damage. People with neuropathy or nerve entrapment sometimes report improvement. The peptides for nerve damage page covers this in detail.
Wound Healing and Skin Repair
Cuts, surgical incisions, and burns show faster closure rates with BPC-157. The improved blood supply reduces infection risk. Some users report less scarring from injuries sustained while on a BPC-157 protocol, likely from better-organized collagen deposition.
Cardiovascular Protection
BPC-157 has shown protective effects on the cardiovascular system: preventing arrhythmias, protecting against certain types of cardiac damage, and improving endothelial function. The nitric oxide modulation pathway is central here. Not a cardiac drug, but an added systemic benefit.
Neuroprotection and Brain Injury Recovery
One of the most underrated benefit categories.
Animal studies show BPC-157 protects dopaminergic neurons against MPTP-induced damage (a model used for Parkinson's research) and accelerates recovery after traumatic brain injury. The mechanism appears to involve preserving nitric oxide signaling and reducing neuroinflammation in damaged brain tissue. User reports for post-concussion symptoms and persistent cognitive fog after head impacts are common, though human trials remain absent.
Mental Health: Anxiety and Depression via the Gut–Brain Axis
BPC-157's effects on mood emerge from its primary GI mechanism: a healthier gut produces healthier serotonin and dopamine signaling. Animal models show clear anxiolytic and antidepressant-like effects, especially in stress-induced models. Many users with chronic gut issues report unexpected mood lift alongside the physical healing. For the deeper protocol context see our BPC-157 for anxiety and depression guide.
Gastric Protection: NSAIDs, Alcohol, and Corticosteroids
BPC-157 protects the stomach lining against the most common chemical insults: chronic NSAID use, alcohol exposure, and corticosteroid therapy. It's not just symptom relief; the rat model literature shows BPC-157 prevents the actual erosion and ulceration these drugs cause. For people who need to take NSAIDs long-term for joint pain (or are stuck on a corticosteroid course), this protective effect is one of the most well-replicated findings in the entire BPC-157 literature.
BPC-157 Results Timeline: What to Expect Week by Week
Results scale with the type of injury and the dose, but the typical progression is consistent enough to map out. Use this as a baseline expectation, not a guarantee.
For documented before/after cases from real users, see our BPC-157 before and after results gallery.
BPC-157 Dosage
Two routes, different use cases.
Subcutaneous Injection (most common)
Inject into abdominal fat (subcutaneous). Systemic distribution means you don't need to inject at the injury site. Use the reconstitution calculator to determine how much bacteriostatic water to add for your dose.
Oral Capsules
500-1,000 mcg daily for gut-specific goals. Lower systemic bioavailability than injection but delivers the peptide directly to the GI tract. Best for IBS, leaky gut, NSAID recovery, and ongoing gut maintenance. No injection required.
Full protocols are covered on the BPC-157 dosage page.
BPC-157 Side Effects
Minimal and predictable.
BPC-157 has one of the most favorable safety profiles in the peptide space:
- Injection site redness: Most common, mild, resolves within hours. Rotate sites.
- Nausea: Occasional, usually from injecting on an empty stomach. Eating beforehand helps.
- Mild dizziness: Uncommon, typically at higher doses only.
- Fatigue: Rare, first few days of a cycle.
No serious adverse events have been widely reported at standard doses. The main theoretical concern: BPC-157's angiogenic activity means people with active cancer should consult their oncologist before use, as promoting new blood vessel formation could theoretically support tumor vascularization. No such cases have been documented, but the mechanism warrants caution.
Full side effect breakdown on the BPC-157 side effects page.
BPC-157 + TB-500: The Wolverine Stack
The most popular peptide stack for a reason.
BPC-157 and TB-500 target different bottlenecks in healing:
BPC-157 creates the infrastructure. TB-500 brings the workers. Together, they cover the two biggest bottlenecks: blood supply and cell delivery. The Wolverine Stack from Ascension Peptides combines both in one product. The Wolverine Stack dosage page covers the combined protocol.
One caution on "together is better." The only head-to-head test so far, a 2026 Achilles tendon-repair study in 32 lab animals, found TB-500 alone gave the clearest gains in tendon strength and structure, and the combination added no benefit over either peptide alone (Biçer et al., Jt Dis Relat Surg 2026, PMID 42542926). Blends are also outside the October 2026 HHS compounding policy, which covers single-ingredient products only.
For broader healing coverage that also includes anti-inflammatory and skin benefits, the KLOW blend adds GHK-Cu and KPV to the BPC-157 + TB-500 foundation.
BPC-157 vs Other Healing Peptides
BPC-157 is the most popular healing peptide, but it's not the only one. Here's how it stacks up against the alternatives people most often consider.
Most BPC-157 users eventually stack it with TB-500 (see the Wolverine Stack below) once the basics are working. For a fuller comparison of injury-recovery peptides see our guide on BPC-157 alternatives.
Where to Buy BPC-157
Three routes, different tradeoffs.
Compounding pharmacy (prescription required): The most regulated route. Requires a prescription from a physician or telehealth platform. Pharmacies compound BPC-157 under USP 797 sterile standards. Quality is verified but cost is higher. Since October 28, 2026 this route is covered by the HHS enforcement-discretion policy for single-ingredient BPC-157 by injection, by mouth or on the skin.
Licensed peptide supplier: Companies like Ascension Peptides offer BPC-157 with independent third-party testing and certificates of analysis. Available without a traditional prescription in most cases. Verify CoA documentation before purchasing.
Telehealth platform: Growing number of platforms provide physician consultation, prescription, and peptide delivery in one package. Convenient but costs $150-$300/month including the consultation fee.
Regardless of source, verify: independent third-party purity testing (not just in-house), HPLC or mass spectrometry analysis, sterile compounding certification for injectables. The best peptide vendors page covers what to check.
BPC-157 Legal Status
Compoundable by prescription, still not approved.
As of November 2026, BPC-157 is not FDA-approved for any therapeutic indication. On July 23, 2026, FDA's advisory committee voted 8–6 with 1 abstention to recommend it for the 503A bulks list. On October 28, 2026, HHS issued an interim policy under which it will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound single-ingredient BPC-157 acetate for subcutaneous, intramuscular, oral or topical use with a patient-specific prescription (Federal Register, October 30, 2026, 91 FR 68526). Blends such as BPC-157 + TB-500 are not covered. FDA rulemaking to add BPC-157 to the bulks list is still pending, and HHS can revisit the policy.
In practice: BPC-157 is legal to prescribe and legal to compound as a single ingredient under the policy's conditions, and legal to possess for personal use in the United States. Vials sold online with "laboratory use" labels sit outside the policy. Details: what the HHS peptide policy says and how the July 2026 FDA vote went.
Frequently Asked Questions
Sources
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157. Front Pharmacol. 2022;13:1026182. PMID 36588717
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg. 2026;92(3). PMID 42885452
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list; content current as of April 22, 2026). fda.gov
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026 (91 FR 68526). federalregister.gov; AJMC. HHS draft policy eases enforcement on 6 compounded peptides (October 29, 2026). ajmc.com
- RAPS. FDA advisory committee backs two controversial peptides (July 23, 2026). raps.org
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. BPC-157 has not been evaluated by the FDA for any therapeutic use. Individual results vary. Consult a licensed healthcare provider before starting any peptide protocol.



